ClearNote Health to Present Advanced Pancreatic Cancer Detection Test at AACR 2026
ClearNote Health, a company focused on early cancer detection, is set to present its Avantect® Pancreatic Cancer Test at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego. The test, which utilizes the company's Virtuoso™ epigenomics platform, offers a noninvasive method to detect pancreatic cancer with a sensitivity of 82.6% and specificity of 97.5%. This technology measures active biological differences between cancerous and healthy cells using a blood sample. The test is particularly aimed at high-risk groups, such as those with genetic predispositions or a family history of pancreatic cancer. ClearNote Health will also present data on the use of cell-free DNA-based epigenomic profiling to predict treatment responses, which could lead to the development of new blood-based biomarkers. 
